Abpro Holdings (ABPO) Non-Current Assets (2022 - 2026)
Abpro Holdings' (ABPO) quarterly Non-Current Assets came in at $164000.0 in Q1 2026, down 71.63% YoY from $578000.0 in Q1 2025, and down 1.8% on a QoQ basis from $167000.0 in Q4 2025.
Abpro Holdings (ABPO) Non-Current Assets (2022 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 5 years of Non-Current Assets data on file, last reported at $164000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 71.63% year-over-year to $164000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 92.04% YoY) and the FY2025 annual result came in at $167000.0, down 81.13% from the prior year.
- Non-Current Assets eased to $164000.0 in Q1 2026, from $167000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $313.1 million in Q1 2023 to a low of $164000.0 in Q1 2026.
- A 5-year average of $96.5 million and a median of $7.5 million in 2024 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 2.37% in 2023, down 99.57% in 2023.
- Tracing ABPO's Non-Current Assets over 5 years: stood at $309.8 million in 2022, then plunged by 99.57% to $1.3 million in 2023, then slumped by 32.95% to $885000.0 in 2024, then tumbled by 81.13% to $167000.0 in 2025, then fell by 1.8% to $164000.0 in 2026.
- The last three Non-Current Assets figures came in at $164000.0 (Q1 2026), $167000.0 (Q4 2025), and $478000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | 162,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 164,000.00 |
| Dec 31, 2025 | 167,000.00 |
| Sep 30, 2025 | 478,000.00 |
| Jun 30, 2025 | 415,000.00 |
| Mar 31, 2025 | 578,000.00 |
| Dec 31, 2024 | 885,000.00 |
| Sep 30, 2024 | 6.30 Mn |
| Jun 30, 2024 | 7.62 Mn |
| Mar 31, 2024 | 7.51 Mn |
| Dec 31, 2023 | 1.32 Mn |
| Sep 30, 2023 | 36.47 Mn |
| Jun 30, 2023 | 36.00 Mn |
| Mar 31, 2023 | 313.07 Mn |
| Dec 31, 2022 | 309.79 Mn |
| Sep 30, 2022 | 307.55 Mn |
| Jun 30, 2022 | 306.07 Mn |
| Mar 31, 2022 | 305.83 Mn |